Phase 3 Readout~month

Phase 3 Topline: A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effic

Name: Phase 3 Topline: A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effic
Start: 2028-07-01

July 1, 2028

Company: Vera Therapeutics, Inc. (VERA)
Drug: iga
Indication: IgA Nephropathy; Berger Disease

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effic — VERA Phase 3 Readout | BioSniper